Hemostatic effects of aprotinin, tranexamic acid and ε-aminocaproic acid in primary cardiac surgery

被引:57
作者
Casati, V
Guzzon, D
Oppizzi, M
Cossolini, M
Torri, G
Calori, G
Alfieri, O
机构
[1] Univ Milan, Hosp San Raffaele, Dept Cardiothorac Anesthesia & Intens Care, Epidemiol Unit, Milan, Italy
[2] Univ Milan, Hosp San Raffaele, Dept Cardiac Surg, Milan, Italy
关键词
D O I
10.1016/S0003-4975(99)00866-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. The effects of E-aminocaproic acid (EACA) and tranexamic acid (TA) on bleeding and allogeneic transfusions, and the cost of pharmacological and transfusional treatment were compared to aprotinin (AP). Methods. We randomized 210 patients subjected to elective cardiac surgery. Of these, 68 patients received EACA (a bolus of 5 g, an infusion of 2 g/h, and 2.5 g in the priming), 72 patients received TA (a bolus of 1 g, an infusion of 400 mg/h, and 500 mg in the priming), and 70 patients received AP (a bolus of 280 mg, an infusion of 70 mg/h, and 280 mg in the priming). Postoperative blood loss and homologous transfusions were collected and the cost of pharmacological treatment and homologous transfusions were calculated. Results. Bleeding but not allogeneic transfusions was significantly higher in the EACA group (467 +/- 234 versus TA, 311 +/- 231 versus AP, 283 +/- 233; p < 0.001), Costs of pharmacological and transfusional treatment were significantly lower in the TA group ($58.10 +/- $105.10) versus the EACA group ($100.70 +/- $158.60) versus the AP group ($432.60 +/- $128.70) (p < 0.0001). Conclusions. Compared to AP, TA has the same effects on bleeding and transfusions, but with a significant reduction of costs. Patients treated with EACA showed a significantly higher postoperative bleeding with an increased trend of transfusion requirement. (C) 1999 by The Society of Thoracic Surgeons.
引用
收藏
页码:2252 / 2256
页数:5
相关论文
共 22 条
  • [1] COMPARISON OF THE EFFECTS OF APROTININ AND TRANEXAMIC ACID ON BLOOD-LOSS AND RELATED VARIABLES AFTER CARDIOPULMONARY BYPASS
    BLAUHUT, B
    HARRINGER, W
    BETTELHEIM, P
    DORAN, JE
    SPATH, P
    LUNDSGAARDHANSEN, P
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1994, 108 (06) : 1083 - 1091
  • [2] COFFEY A, 1995, AM SURGEON, V61, P566
  • [3] APROTININ - A REVIEW OF ITS PHARMACOLOGY AND THERAPEUTIC EFFICACY IN REDUCING BLOOD-LOSS ASSOCIATED WITH CARDIAC-SURGERY
    DAVIS, R
    WHITTINGTON, R
    [J]. DRUGS, 1995, 49 (06) : 954 - 983
  • [4] DEPEPPO AP, 1995, TEX HEART I J, V22, P231
  • [5] APROTININ PROLONGS WHOLE-BLOOD ACTIVATED PARTIAL THROMBOPLASTIN TIME BUT NOT WHOLE-BLOOD PROTHROMBIN TIME IN PATIENTS UNDERGOING CARDIAC-SURGERY
    DESPOTIS, GJ
    ALSOUFIEV, A
    GOODNOUGH, LT
    LAPPAS, DG
    [J]. ANESTHESIA AND ANALGESIA, 1995, 81 (05) : 919 - 924
  • [6] FATAL ANAPHYLACTIC SHOCK AFTER APROTININ REEXPOSURE IN CARDIAC-SURGERY
    DIEFENBACH, C
    ABEL, M
    LIMPERS, B
    LYNCH, J
    RUSKOWSKI, H
    JUGERT, FK
    BUZELLO, W
    [J]. ANESTHESIA AND ANALGESIA, 1995, 80 (04) : 830 - 831
  • [7] High-dose ε-aminocaproic acid versus aprotinin:: Antifibrinolytic efficacy in first-time coronary operations
    Eberle, B
    Mayer, E
    Hafner, G
    Heinermann, J
    Dahm, M
    Prellwitz, W
    Dick, W
    Oelert, H
    [J]. ANNALS OF THORACIC SURGERY, 1998, 65 (03) : 667 - 673
  • [8] METAANALYSIS OF PROPHYLACTIC DRUG-TREATMENT IN THE PREVENTION OF POSTOPERATIVE BLEEDING
    FREMES, SE
    WONG, BI
    LEE, E
    MAI, R
    CHRISTAKIS, GT
    MCLEAN, RF
    GOLDMAN, BS
    NAYLOR, CD
    [J]. ANNALS OF THORACIC SURGERY, 1994, 58 (06) : 1580 - 1588
  • [9] Prophylactic tranexamic acid and ε-aminocaproic acid for primary myocardial revascularization
    Hardy, JF
    Bélisle, S
    Dupont, C
    Harel, F
    Robitaille, D
    Roy, M
    Gagnon, L
    [J]. ANNALS OF THORACIC SURGERY, 1998, 65 (02) : 371 - 376
  • [10] HOLLOWAY DS, 1988, THROMB HAEMOSTASIS, V59, P62